GeneDx director acquires 1,146 shares via RSUs

GeneDx Holdings Corp. (WGS) director Thomas Fuchs reported the settlement of 1,146 Restricted Stock Units into 1,146 shares of Class A Common Stock on September 17, 2026, for no cash consideration.

Rhea-AI Filing Summary

GeneDx Holdings Corp. (WGS) director Thomas Fuchs reported the settlement of 1,146 Restricted Stock Units into 1,146 shares of Class A Common Stock on September 17, 2026, for no cash consideration. After these transactions, he holds 1,146 common shares and 2,292 RSUs directly. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

1,146 shares exercised/converted

Exercise 2 txns

Insider Fuchs Thomas

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit F1, F2	1,146	$0.00	$0.00
Exercise	Class A Common Stock F1	1,146	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 2,292 contracts (Direct); Class A Common Stock — 1,146 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
2. F2. The award shall vest in three equal installments on September 17, 2026, September 17, 2027, and September 17, 2028, subject to the reporting person's continued service to the Issuer on the applicable vesting date.

Key Figures

RSUs converted: 1,146 units Shares acquired: 1,146 shares Common shares held after transaction: 1,146 shares +2 more

5 metrics

RSUs converted 1,146 units Restricted Stock Units settled into Class A Common Stock on September 17, 2026

Shares acquired 1,146 shares Class A Common Stock received upon RSU settlement on September 17, 2026

Common shares held after transaction 1,146 shares Direct holdings of Class A Common Stock after reported transactions

RSUs held after transaction 2,292 units Direct Restricted Stock Unit holdings following the conversions

RSU vesting schedule 3 equal installments Vesting on September 17, 2026, 2027, and 2028, subject to continued service

Key Terms

Restricted Stock Unit, Class A Common Stock, contingent right, vesting

4 terms

Restricted Stock Unit financial

"Each restricted stock unit ("RSU") represents a contingent right to receive 1 share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Class A Common Stock financial

"1 share of the Issuer's Class A Common Stock upon settlement for no consideration"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

contingent right financial

"represents a contingent right to receive 1 share of the Issuer's Class A"

vesting financial

"The award shall vest in three equal installments on September 17, 2026"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did director Thomas Fuchs report at GeneDx Holdings Corp. (WGS)?

He reported the exercise and settlement of 1,146 Restricted Stock Units into 1,146 shares of Class A Common Stock on September 17, 2026, with a reported price of $0.00 per share, reflecting no cash consideration for the conversion.

How many GeneDx (WGS) Class A shares does Thomas Fuchs hold after this Form 4?

After the reported transactions, Thomas Fuchs directly holds 1,146 shares of GeneDx Class A Common Stock. These shares were acquired upon settlement of previously granted Restricted Stock Units.

How many Restricted Stock Units does Thomas Fuchs still hold in GeneDx (WGS)?

Following the September 17, 2026 transactions, Thomas Fuchs directly holds 2,292 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Class A Common Stock upon settlement for no consideration.

What are the vesting terms for Thomas Fuchs’s GeneDx (WGS) RSU award?

The RSU award is scheduled to vest in three equal installments on September 17, 2026, September 17, 2027, and September 17, 2028, subject to his continued service to GeneDx Holdings Corp. on each applicable vesting date.

Was Thomas Fuchs’s GeneDx (WGS) Form 4 transaction under a Rule 10b5-1 plan?

No. The filing indicates that no Rule 10b5-1 trading plan is reported in connection with these transactions by director Thomas Fuchs.

Did Thomas Fuchs buy or sell GeneDx (WGS) shares for cash in this Form 4?

No. The reported activity reflects exercise or conversion of RSUs into common stock at a reported price of $0.00 per share, meaning there was no cash purchase or sale of GeneDx shares in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/18/2026 - 04:38 PM Accepted by SEC EDGAR 09/18/2026 - 04:37 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fuchs Thomas

(Last) (First) (Middle)

C/O GENEDX HOLDINGS CORP.

333 LUDLOW ST., NORTH TOWER, 6TH FLOOR

(Street)

STAMFORD CONNECTICUT 06902

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GeneDx Holdings Corp. [ WGS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	09/17/2026		M		1,146	A	$0(1)	1,146	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	09/17/2026		M			1,146	(2)	(2)	Class A Common Stock	1,146	$0	2,292	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

2. The award shall vest in three equal installments on September 17, 2026, September 17, 2027, and September 17, 2028, subject to the reporting person's continued service to the Issuer on the applicable vesting date.

	/s/ Bridget Brown, Attorney-in-Fact	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)